According to Zacks, “Mirum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company’s product candidate consists of maralixibat, an investigational oral drug in development for progressive familial intrahepatic cholestasis and Alagille syndrome. Mirum Pharmaceuticals Inc. is based in Foster City, United States. “
Several other equities analysts have also recently weighed in on MIRM. Citigroup began coverage on Mirum Pharmaceuticals in a research note on Monday, August 12th. They set a buy rating and a $21.00 price objective on the stock. Guggenheim began coverage on Mirum Pharmaceuticals in a research note on Monday, August 12th. They set a buy rating and a $18.00 price objective on the stock. Evercore ISI began coverage on Mirum Pharmaceuticals in a research note on Monday, August 12th. They set an outperform rating and a $25.00 price objective on the stock. Roth Capital began coverage on Mirum Pharmaceuticals in a research note on Monday, August 12th. They set a buy rating and a $33.00 price objective on the stock. Finally, Raymond James began coverage on Mirum Pharmaceuticals in a research note on Monday, August 12th. They set an outperform rating and a $28.00 price objective on the stock. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock has an average rating of Buy and a consensus target price of $22.25.
NASDAQ:MIRM traded up $0.22 on Tuesday, reaching $7.41. 65,300 shares of the stock traded hands, compared to its average volume of 31,334. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.64 and a current ratio of 11.85. The firm has a 50 day moving average of $8.37. Mirum Pharmaceuticals has a 1-year low of $6.80 and a 1-year high of $15.50.
Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.25). Research analysts predict that Mirum Pharmaceuticals will post -4.84 EPS for the current year.
In other Mirum Pharmaceuticals news, CEO Christopher Peetz bought 9,070 shares of the stock in a transaction dated Monday, September 9th. The shares were bought at an average cost of $11.02 per share, for a total transaction of $99,951.40. Also, SVP Ian Clements bought 4,000 shares of the stock in a transaction dated Friday, September 6th. The shares were acquired at an average price of $11.51 per share, for a total transaction of $46,040.00. Insiders have bought a total of 21,432 shares of company stock worth $232,684 over the last quarter.
An institutional investor recently bought a new position in Mirum Pharmaceuticals stock. Dean Capital Investments Management LLC bought a new position in shares of Mirum Pharmaceuticals (NASDAQ:MIRM) during the third quarter, according to its most recent filing with the SEC. The fund bought 45,420 shares of the company’s stock, valued at approximately $457,000. Dean Capital Investments Management LLC owned 0.20% of Mirum Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 18.42% of the company’s stock.
Mirum Pharmaceuticals Company Profile
Mirum Pharmaceuticals, Inc, a clinical-stage therapeutics company, develops and produces therapies for patients with cholestatic liver diseases with a focus on rare pediatric conditions. The company's lead product candidate is maralixibat, a Phase 3-ready investigational oral drug with indications, including Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC).
Featured Article: What is diluted earnings per share (Diluted EPS)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.